{'fraction_non_alphanumeric': 0.029787234042553193, 'fraction_numerical': 0.01276595744680851, 'mean_word_length': 5.038461538461538, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
From best supportive care to early palliative care.

In 1990, Woods et al. [1] published a trial of cisplatin with vindesine versus supportive care only in advanced nonsmall cell lung cancer (NSCLC) patients. Although the overall survival of the chemotherapy group was longer, they concluded that chemotherapy cannot be recommended as routine treatment. Since then, a series of other trials established the value of chemotherapy for the management of advanced NSCLC [2].